EN DE
Watch MannKind Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MannKind Corp (MNKD) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of MannKind Corp stock $1.70, price $3.90, that is 56.4% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MC MannKind Corp logo Some data Nov 6, 2026

MannKind Corp

MNKD · US
Very expensive, weak quality

Our calculation puts a fair price 56% below what the stock costs today.

Revenue last quarter +43% vs. a year ago.
Mixed Growth (revenue 5y +39.9 %/yr in USD)
Negative equity (buybacks among others)
Insiders sold $791,323 (6M)
Some data
Fair value $1.70 · Strongly overvalued (−56.4%)
Quality 39/100
Loss-making · -11.1% net margin (TTM) · excl. one-off gain FY2025 -12.4%
Negative free cash flow over the last twelve months
Trails peers (3/10)
Narrow moat 21/100
Watch MannKind Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.44 $2.28 Fair Value $1.70 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $2.28 – $7.44 · fair‑value band $0.8100 – $2.58 · the $3.90 price screens above the $1.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow MannKind in your weekly email

Every Wednesday you see whether MannKind is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.

Show moreShow less

It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.

Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease.

The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701.

It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.

MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Stock analysis

MannKind Corp (MNKD) currently trades at $3.90, while our model-based Fair Value estimate is $1.70, 56% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $2.07 per share, and 0 of the 21 models we run sit above the $3.90 price.

Bear case: the Earnings-Based group reads lowest at $0.7500, and 21 of the 21 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $0.8100 (bear) to $2.58 (bull), the price of $3.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

MannKind Corp reported revenue of $349M in FY2025 versus $75.4M in FY2021, a compound +46.7%/yr. Reported net income was $5.9M in FY2025.

Key figures

Market cap $1.2B Small · P/S ratio 3.07 · EPS (TTM) $−0.1400 · Net margin −11.1% · Return on assets (EBIT) −2.2% (5-year average) · Operating margin −0.8% · Revenue (TTM) $394M · Revenue growth (YoY) +42.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (medium confidence).

What moves the price

The share trades about 37% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −56%, MNKD screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($0.2400 to $3.71). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.8100 Fair Value $1.70 Bull $2.58
Price $3.90 · Downside -56.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $0.8100 $1.01 $1.18 74
Owner Earnings n/a $0.5500 $1.75 71
Growth DCF $0.2300 $0.9100 $1.97 68
All 21 models by family
DCF Models
FCF DCF $0.3000 $0.7600 $2.13 67
Owner Earnings n/a $0.5500 $1.75 71
5Y Revenue Exit $1.08 $2.66 $5.98 64
5Y EBITDA Exit $1.47 $3.44 $7.31 67
5Y P/E Exit n/a $0.2400 $0.8100 65
10Y Revenue Exit $0.7400 $2.97 $4.54 62
10Y EBITDA Exit $1.06 $3.71 $8.46 59
10Y P/E Exit n/a $0.5100 $1.29 59
Earnings-Based
Graham-Dodd $0.1200 $0.8600 $1.21 61
Lynch FV $0.4500 $0.6400 $0.8300 59
PEG = 1.0 $0.4500 $0.6400 $0.8300 55
EPV $0.8100 $1.01 $1.18 74
Multiples
P/E Multiple $0.3000 $0.4000 $0.5000 63
P/S Multiple $0.2300 $0.3100 $0.3900 58
EV/EBIT $1.64 $2.60 $3.56 64
EV/EBITDA $1.53 $2.46 $3.38 66
EV/Revenue $0.8100 $1.70 $2.58 51
Growth DCF
Growth DCF $0.2300 $0.9100 $1.97 68
Rev-Margin DCF $1.29 $3.14 $7.01 64
Economic Profit
ROIC Compounder $1.22 $2.07 $3.09 67
Growth Earnings
Growth-Adj P/E $0.5900 $0.8500 $1.10 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 33
How much profit the company makes from its sales and capital
Quality Growth 38
Are margins and returns getting better?
Cashflow 56
Do the profits arrive as real cash?
Financial strength 14
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 33
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 21
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $791,323 and none bought.

  • SaleSteven B. BinderDirector5× since May 12, 2026: 181,085 shares, avg. $3.78$683,703Sep 25, 202610b5-1 plan
  • SaleDavid ThomsonEVP Genl Counsel & Secretary3× since Dec 2, 2025: 174,922 shares, avg. $5.32$930,755Jul 17, 202610b5-1 plan
  • BuyMichael CastagnaChief Executive Officer, Director100,000 shares at $2.59$259,000Mar 10, 2026
  • SaleStuart A TrossChief People & Workpl Officer47,006 shares at $6.33$297,548Jan 8, 202610b5-1 plan
  • SaleMichael CastagnaChief Executive Officer, Director3× since Dec 2, 2025: 215,840 shares, avg. $5.79$1.2MDec 17, 202510b5-1 plan
  • SaleSanjay R SinghEVP Technical Operations18,777 shares at $5.03$94,448Nov 14, 202510b5-1 plan

Plus 14 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.9%
Start year 2020 (pandemic)
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−70.7% (2019) → 25.4% (2024)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+47.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.1%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +43.7% a year for the price and +12.4% for the forecasts.
Forecast 2026 (sales)+26.6%
Forecast 2027 (sales)+14.8%
Projected 2028 (sales)+13.2%
Projected 2029 (sales)+11.6%
Projected 2030 (sales)+10.0%

MNKD screens overvalued: fair value 56% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare MannKind Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −56.4% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 0.7% · Above median
Net margin (12 months) −11.1% · Below median
Operating margin (12 months) −0.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 42.9% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 3.06× · Cheaper than median
Price / free cash flow (fiscal year) 88.1× · Priciest 25%
EV/EBITDA 74.2× · Priciest 25%
PEG 4.39× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs MNKD
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs MNKD
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs MNKD
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs MNKD
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs MNKD
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs MNKD
argenx SE ARGX $927.21 $908.40 −2% vs MNKD
CSL Limited CSL A$202.04 A$183.04 −9% vs MNKD
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs MNKD
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs MNKD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MannKind Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MannKind Corp Fair Value". https://www.fairvalue-calculator.com/stock/MNKD

Frequently asked questions

Is MannKind Corp (MNKD) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $1.70 versus a price of $3.90, about 56% lower (overvalued).
What is the fair value of MNKD?
Our model-based fair value for MannKind Corp is $1.70 (as of Nov 6, 2026), built from audited fundamentals. The current price: $3.90.
What is the quality score of MNKD?
MannKind Corp has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MannKind Corp (MNKD)?
Our model-based price target is the fair value of $1.70 (as of Nov 6, 2026) from 21 valuation models. Cautious scenario $0.8100, optimistic scenario $2.58. It is a calculation from audited fundamentals, not an analyst target.
What is the MannKind Corp stock forecast for 2026?
Our models put fair value at $1.70, about 56% lower versus a price of $3.90 (overvalued). Cautious scenario $0.8100, optimistic scenario $2.58. The calculation is refreshed regularly with new filings.
What is the revenue of MannKind Corp (MNKD)?
MannKind Corp reported trailing-twelve-month revenue of about $394M (latest available figure, as of Nov 6, 2026).
What growth is priced into MannKind Corp (MNKD)?
For today's price to be fair in a discounted-cash-flow model, MannKind Corp would have to grow free cash flow by +47.1 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +39.9 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of MNKD use?
Our models discount MannKind Corp at 11.5 %: a base by market capitalisation (small), damped by beta 1.09, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For MannKind Corp that is +47.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.5 %) and the same formula as our fair value.
How much growth has MannKind Corp (MNKD) delivered so far?
Over the past 5 years revenue at MannKind Corp grew +39.9 % a year. The price currently implies free-cash-flow growth of +47.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of MannKind Corp (MNKD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into MannKind Corp (+47.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of MannKind Corp (MNKD)?
The free-cash-flow yield on the price is 1.14 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow MannKind Corp produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of MannKind Corp (MNKD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MannKind Corp it is $1.70 per share (as of Nov 6, 2026), against a price of $3.90. It is the blended result of 21 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is MannKind Corp stock overvalued or undervalued in 2026?
As of Nov 6, 2026, MNKD trades above its calculated fair value: price $3.90, fair value $1.70, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MNKD?
No. The price is what the market pays today ($3.90); the fair value is what the company's own numbers justify ($1.70). For MannKind Corp the two are $2.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is MannKind Corp worth?
The market values MannKind Corp at about $1.2B (market capitalisation, as of Nov 6, 2026). Per share that is $3.90; our models calculate a fair value of $1.70 per share.
What do the bullish and bearish scenarios say about MNKD?
Our models span a range for MannKind Corp: cautious scenario $0.8100, base $1.70, optimistic $2.58 per share (as of Nov 6, 2026, price $3.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MNKD?
The PEG ratio of MannKind Corp is 4.39 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of MannKind Corp (MNKD)?
Balance-sheet figures for MannKind Corp (as of Nov 6, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is MNKD from its 52-week high?
MannKind Corp trades at $3.90, about 37% below its 52-week high of $6.21 and 71% above the low of $2.28 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.70 is for.
Which stocks are comparable to MannKind Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MannKind Corp stock attractive at the current price?
The data as of Nov 6, 2026: price $3.90, calculated fair value $1.70 (−56%), Quality Score 39/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MNKD calculated?
We run MannKind Corp through 21 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $1.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. MannKind Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MannKind Corp (MNKD)?
The closing price on Nov 6, 2026 was $3.90. Our model-based fair value is $1.70, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MannKind Corp right now?
The price sits above even our optimistic bull case ($2.58). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($0.8100 to $2.58). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of MannKind Corp

How large is the market capitalisation of MannKind Corp (MNKD)?
The market capitalisation of MannKind Corp is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MannKind Corp (MNKD)?
The price-to-sales ratio of MannKind Corp is 3.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of MannKind Corp (MNKD)?
Earnings per share at MannKind Corp are $−0.1400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of MannKind Corp (MNKD)?
The net margin of MannKind Corp is −11.1% (last twelve months), excl. one-off gain FY2025 −12.4%. How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of MannKind Corp (MNKD)?
On an EBIT basis the return on assets of MannKind Corp is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MannKind Corp (MNKD)?
The operating margin of MannKind Corp is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MannKind Corp (MNKD)?
Revenue at MannKind Corp is growing +42.9% versus a year earlier (3y avg +51.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at MannKind Corp (MNKD)?
Earnings per share at MannKind Corp are growing −34.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does MannKind Corp (MNKD) carry?
The net debt of MannKind Corp is $399M (fiscal year 2025, ≈ 29.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch MannKind Corp in the live analysis

One click puts MannKind Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.